Abstract: P919
Type: Poster
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Background: In multiple sclerosis (MS), there is an increasing interest in drugs promoting myelin repair (e.g. Opicinumab or Clemastine). Multifocal visual evoked potentials (mfVEPs) have been suggested as an appropriate technology to monitor the efficacy of these drugs. Addressing the relationship between mfVEPs and disability as well as with markers of neuroaxonal damage in MS is important to define the role of mfVEPs as surrogate end-point in clinical trials and evaluate the impact of myelin repair strategies to prevent disability in MS.
Goal: to evaluate the relationship of mfVEPs with disability and markers of neuroaxonal damage in patients with MS.
Method: We performed a crossectional analysis in 76 patients with MS. Patients underwent examination including global and visual disability scales (low contrast visual acuity (LCVA) and color vision measured by Hardy, Rand Ritter pseudoisochromatic plates (HRR), mfVEPs and spectral domain optical coherence tomography (Spectralis-SD-OCT). We evaluated the association between the mean latency and amplitude of mfVEP and disability and neuroaxonal injury markers using Spearman´s rank correlation test in eyes unaffected with prior optic neuritis (non-ON eyes) and affected eyes (ON-eyes).
Results: We found inverse associations between the mean latency of mfVEPs and visual disability (2.5%LCVA (rho=-0.311; p=0.010 and HRR (rho=-0.423; p< 0.001)) and retinal neuroaxonal injury measured by peripapillary retinal nerve fiber layer (pRNFL) thickness (rho=-0.237; p=0.050) in non-ON eyes. Regarding the amplitude of the mfVEP, we found associations in non-ON eyes with the Expanded Disability Status Scale (rho=-0.277; p=0.020), 2.5%LCVA (rho=0.232; p=0.057), 1.25%LCVA (rho=0.239; p=0.052), HRR (rho=0.329; p=0.007), and pRNFL thickness (rho=0.263; p=0.029). In ON-eyes, there were associations between the mean latency of mfVEPs and 2.5%LCVA (rho=0.310; p=0.079) and HRR (rho=-0.438; p=0.010) as well as associations between mean amplitude of mfVEPs and 2.5%LCVA (rho=0.419; p=0.014), 1.25%LCVA (rho=0.355; p=0.043), HRR (rho=0.562; p=0.001) and pRNFL thickness (rho=0.561; p< 0.001).
Conclusion: The significant structural-functional correlations between mfVEP, SD-OCT and visual disability in both non-ON and ON-eyes found here supports the use of mfVEP as a marker of axonal and myelin damage in MS as well as its use as a surrogate end-point of efficacy of drugs promoting remyelination
Disclosure: Elena H Martinez-Lapiscina is a researcher in OCTIMS study, an observational study for validating OCT as a biomarker for MS sponsored by Novartis (this study is not involving any specific drug). She has received personal compensation for activities with Biogen Idec and Genzyme as a speaker. She has received grants from the Instituto de Salud Carlos III (CM13/00150 and MV15/00012) and Fundació Marató TV3 (20142030). She has received speaking honoraria from Biogen and Genzyme and travel reimbursement from TEVA, Bayer, Merck-Serono and Roche for international and national meetings over the last 3 years.
Ana Isabel Tercero-Uribe has nothing to disclose
Salut Alba-Arbalat has nothing to disclose
Nuria Solà-Valls has nothing to disclose
Magi Andorra has nothing to disclose
María Sepúlveda has nothing to disclose
Ana Maria Guerrero-Zamora has nothing to disclose
Sara Llufriu has nothing to disclose
Irati Zubizarreta has nothing to disclose
Yolanda Blanco has nothing to disclose
Ruben Torres-Torres has nothing to disclose
Bernardo Sánchez-Dalmau is a researcher in OCTIMS study
Albert Saiz has received compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. He is a researcher in OCTIMS study. Founding: He received grants from the Instituto de Salud Carlos III (RD12/0032/0002)
Joan Santamaria has nothing to disclose
Pablo Villoslada has received consultancy fees from Heidelberg Engineering regarding the clinical applications of OCT; serves as academic editor of Current Treatment Options in Neurology, Neurology & Therapy, Multiple Sclerosis & Demyelinating Disorders, PLOS One, and MS in focus; is founder and hold stocks in Bionure and Spire Bioventures; has received consultancy fees from Roche, Novartis, Health Engineering, and stock options from Mint-Labs; has received unrestricted grants from Genzyme, Roche and Novartis; and is a researcher in OCTIMS study. Founding: He received grants from the Instituto de Salud Carlos III (PI15/00061 and RD012/0060/01)
Abstract: P919
Type: Poster
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Background: In multiple sclerosis (MS), there is an increasing interest in drugs promoting myelin repair (e.g. Opicinumab or Clemastine). Multifocal visual evoked potentials (mfVEPs) have been suggested as an appropriate technology to monitor the efficacy of these drugs. Addressing the relationship between mfVEPs and disability as well as with markers of neuroaxonal damage in MS is important to define the role of mfVEPs as surrogate end-point in clinical trials and evaluate the impact of myelin repair strategies to prevent disability in MS.
Goal: to evaluate the relationship of mfVEPs with disability and markers of neuroaxonal damage in patients with MS.
Method: We performed a crossectional analysis in 76 patients with MS. Patients underwent examination including global and visual disability scales (low contrast visual acuity (LCVA) and color vision measured by Hardy, Rand Ritter pseudoisochromatic plates (HRR), mfVEPs and spectral domain optical coherence tomography (Spectralis-SD-OCT). We evaluated the association between the mean latency and amplitude of mfVEP and disability and neuroaxonal injury markers using Spearman´s rank correlation test in eyes unaffected with prior optic neuritis (non-ON eyes) and affected eyes (ON-eyes).
Results: We found inverse associations between the mean latency of mfVEPs and visual disability (2.5%LCVA (rho=-0.311; p=0.010 and HRR (rho=-0.423; p< 0.001)) and retinal neuroaxonal injury measured by peripapillary retinal nerve fiber layer (pRNFL) thickness (rho=-0.237; p=0.050) in non-ON eyes. Regarding the amplitude of the mfVEP, we found associations in non-ON eyes with the Expanded Disability Status Scale (rho=-0.277; p=0.020), 2.5%LCVA (rho=0.232; p=0.057), 1.25%LCVA (rho=0.239; p=0.052), HRR (rho=0.329; p=0.007), and pRNFL thickness (rho=0.263; p=0.029). In ON-eyes, there were associations between the mean latency of mfVEPs and 2.5%LCVA (rho=0.310; p=0.079) and HRR (rho=-0.438; p=0.010) as well as associations between mean amplitude of mfVEPs and 2.5%LCVA (rho=0.419; p=0.014), 1.25%LCVA (rho=0.355; p=0.043), HRR (rho=0.562; p=0.001) and pRNFL thickness (rho=0.561; p< 0.001).
Conclusion: The significant structural-functional correlations between mfVEP, SD-OCT and visual disability in both non-ON and ON-eyes found here supports the use of mfVEP as a marker of axonal and myelin damage in MS as well as its use as a surrogate end-point of efficacy of drugs promoting remyelination
Disclosure: Elena H Martinez-Lapiscina is a researcher in OCTIMS study, an observational study for validating OCT as a biomarker for MS sponsored by Novartis (this study is not involving any specific drug). She has received personal compensation for activities with Biogen Idec and Genzyme as a speaker. She has received grants from the Instituto de Salud Carlos III (CM13/00150 and MV15/00012) and Fundació Marató TV3 (20142030). She has received speaking honoraria from Biogen and Genzyme and travel reimbursement from TEVA, Bayer, Merck-Serono and Roche for international and national meetings over the last 3 years.
Ana Isabel Tercero-Uribe has nothing to disclose
Salut Alba-Arbalat has nothing to disclose
Nuria Solà-Valls has nothing to disclose
Magi Andorra has nothing to disclose
María Sepúlveda has nothing to disclose
Ana Maria Guerrero-Zamora has nothing to disclose
Sara Llufriu has nothing to disclose
Irati Zubizarreta has nothing to disclose
Yolanda Blanco has nothing to disclose
Ruben Torres-Torres has nothing to disclose
Bernardo Sánchez-Dalmau is a researcher in OCTIMS study
Albert Saiz has received compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. He is a researcher in OCTIMS study. Founding: He received grants from the Instituto de Salud Carlos III (RD12/0032/0002)
Joan Santamaria has nothing to disclose
Pablo Villoslada has received consultancy fees from Heidelberg Engineering regarding the clinical applications of OCT; serves as academic editor of Current Treatment Options in Neurology, Neurology & Therapy, Multiple Sclerosis & Demyelinating Disorders, PLOS One, and MS in focus; is founder and hold stocks in Bionure and Spire Bioventures; has received consultancy fees from Roche, Novartis, Health Engineering, and stock options from Mint-Labs; has received unrestricted grants from Genzyme, Roche and Novartis; and is a researcher in OCTIMS study. Founding: He received grants from the Instituto de Salud Carlos III (PI15/00061 and RD012/0060/01)